Aytu BioScience

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Aytu BioScience reports robust Q3 performance, eyes growth through innovation

Aytu BioScience delivered strong financial results in Q3 2024, with notable revenue and margin improvements. The company's strategic focus on specialty pharmaceuticals and operational efficiency bodes well for future growth. While challenges like supply chain disruptions exist, Aytu is poised for continued success through innovation and market opportunities.

Aytu BioScience reports robust earnings, focuses on growth strategies

Aytu BioScience demonstrated strong financial performance with improved EBITDA and strategic repositioning
While facing challenges in certain portfolio revenues, the company is focused on growth opportunities
Strategic initiatives like the RxConnect program and product expansion are key strengths
Addressing market challenges and seizing growth opportunities will be crucial for future success

Aytu BioPharma reports first-ever positive net income in Q1 2025

Aytu BioPharma delivered a strong performance in Q1 2025, achieving positive net income, sustained profitability, and operational efficiency amidst market challenges.
The company's focus on optimizing operations, reducing expenses, and pursuing growth opportunities positions it well for future revenue expansion and market competitiveness.
While facing challenges in a dynamic market environment, Aytu BioPharma has opportunities to leverage its strengths in key portfolios and strategic initiatives for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients  ENGLEWOOD, CO / ACCESSWIRE / March 8, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released. The pre-print publication titled "Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study" concluded that endotracheal UVA light treatment was associated with a significant reduction of SARS-CoV-2 viral load and improvement in WHO clinical severity scores.

Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients

Applied Genetic Technologies

Atomera

Co-Diagnostics

Cortexyme Inc

Dynavax Technologies

Sorrento Therapeutics Inc

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

7 Small Stocks Up Big Can Still Double From Here, Analysts Say

Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript

CNOOC

Gold Fields Ltd.

Getty Realty

Lennar

QTS Realty Trust

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Play Stocks With Rising P/E to Realize Solid Gains

Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant upside potential and numerous exciting catalysts to be announced that could drive significant share price value in the very near future.

Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts

Knnate Biopharma

Myovant Sciences

Osmotica Pharmaceuticals Plc

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products.

Why These 4 Health Care Stocks Are Moving Today

First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the Healight™ ultraviolet A light catheter technology. This single center, U.S.-based study evaluated the safety and proof of principle of the Healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with COVID-19.

Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients

Neos Therapeutics

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU). Stockholders will...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.

Gilead Sciences

The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. Gilead Snaps Up Germany Drug Company In $1B Deal: Large-cap pharma Gilead announced Thursday an agreement to acquire German biotech MYR, which focuses on therapeutics for chronic hepatitis delta virus, or HDV, for an upfront payment of 1.15 billion euros ($1.39 billion) in cash, payable upon closing of the transaction, and 300 million euros ($363 million) in potential future milestone payments.

Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September 30th, 2020. In this article we are going to take a look at smart money sentiment towards Aytu BioScience, Inc. (NASDAQ:AYTU).

Where Do Hedge Funds Stand On Aytu BioScience, Inc. (AYTU)?

Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting. A careful review of the data supports an estimate of profitability in the upcoming Q1 and an expected increase in share price based on applying industry average benchmarks.

Aytu BioScience: The Barcode King Is Poised For An Epic Breakout

Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results. Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimate of ($0.03).

Recap: Aytu BioScience Q4 Earnings

Aytu BioScience (NASDAQ: AYTU) releases its next round of earnings this Tuesday, October 06. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

Preview: Aytu BioScience's Earnings

On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report.

Aytu BioScience's Earnings Outlook

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

Aytu Bioscience, Inc. (AYTU) closed at $1.39 in the latest trading session, marking a +1.46% move from the prior day.

Aytu Bioscience, Inc. (AYTU) Outpaces Stock Market Gains: What You Should Know

Is  (AYTU) Outperforming Other Medical Stocks This Year?

Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?

Some small companies are destined to be small forever. Others can grow into massive companies over time.

Surging COVID-19 Cases Could Alter Aytu BioScience’s Path to Profitability

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy

Aytu BioScience: The Next Arbor Pharmaceuticals?

Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Aytu BioScience (AYTU) Stock Might be a Great Pick

Aytu BioScience Inc. (NASDAQ: AYTU) stock has been a huge beneficiary of the coronavirus pandemic.

Aytu BioScience Stock Remains a Coronavirus Play

Aytu BioScience, Inc. (NASDAQ: AYTU) has been one of the biggest winners from COVID-19.

Will All Those Deals Pay Off for Aytu BioScience Stock

Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Aytu BioScience, Inc. (NASDAQ: AYTU) is a specialty pharmaceutical company focused on commercializing novel products related to low testosterone, upper respiratory problems, insomnia, and more.

News for Aytu BioScience Stock (AYTU)